Eligible patients received bevacizumab ( @ mg/kg ) , trastuzumab ( @ mg/kg loading dose followed by @ mg/kg ) , and docetaxel ( @ mg/m@ initially , later amended to @ mg/m@ ) every three weeks for six cycles and then were allowed to receive bevacizumab and trastuzumab alone .